Journal of occupational and environmental medicine · 2026
Pharmacy Utilization Patterns and Polypharmacy as Predictors of High-Cost Workers' Compensation Claims: An Updated Cohort Study of Occupational Ankle Sprains.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tao Xuguang Grant, Iglesias Marcos A, Kalia Nimisha, Leung Nina, Green-McKenzie Judith, Satterfield Robyn, Bernacki Edward J
Аннотация
OBJECTIVE: Evaluate pharmacy utilization patterns as independent predictors of high-cost workers' compensation claims (≥$50,000) for occupational ankle sprains.
METHODS: Pharmacy Benefit Management data were integrated into a 9-year cohort of 18,991 claims. Logistic regression modeled individual drug-class utilization and multi-class combinations, adjusting for demographics, industry, litigations, physical complications, treatments, and comorbidities.
RESULTS: High-cost risk increased significantly with individual utilization of opioids (OR: 2.19; 95% CI: 1.78-2.69) and antiseizure medications (OR: 4.21; 95% CI: 3.28-5.39). While exclusive nonsteroidals use demonstrated no elevated risk (OR: 0.96; 95% CI: 0.76-1.20), polypharmacy involving three or more flagged drug classes was associated with a 7.71-fold increase in cost escalation (CI: 6.08-9.77).
CONCLUSIONS: Early multi-class prescription drug tracking provides a dynamic and real-time indicator of case complexity, allowing interventions from relevant parties to prevent severe financial escalation.
METHODS: Pharmacy Benefit Management data were integrated into a 9-year cohort of 18,991 claims. Logistic regression modeled individual drug-class utilization and multi-class combinations, adjusting for demographics, industry, litigations, physical complications, treatments, and comorbidities.
RESULTS: High-cost risk increased significantly with individual utilization of opioids (OR: 2.19; 95% CI: 1.78-2.69) and antiseizure medications (OR: 4.21; 95% CI: 3.28-5.39). While exclusive nonsteroidals use demonstrated no elevated risk (OR: 0.96; 95% CI: 0.76-1.20), polypharmacy involving three or more flagged drug classes was associated with a 7.71-fold increase in cost escalation (CI: 6.08-9.77).
CONCLUSIONS: Early multi-class prescription drug tracking provides a dynamic and real-time indicator of case complexity, allowing interventions from relevant parties to prevent severe financial escalation.